期刊文献+

卵巢肿瘤细胞体外药物敏感试验临床应用价值

Clinical value of drug sensitivity test of ovarian tumor cells in vitro
下载PDF
导出
摘要 目的探讨三磷酸腺苷—肿瘤体外药敏检测在指导晚期卵巢上皮癌患者化疗中的临床应用价值。方法回顾性分析我科住院的晚期卵巢上皮癌20例患者病历,根据药敏实验结果选取敏感化疗方案9例为实验组,采取卵巢上皮癌化疗的一线化疗方案(铂类+紫杉醇)化疗者11例为对照组,比较两组近期临床疗效。结果实验组临床近期疗效好于对照组(Z=-3.636,P<0.001)。结论三磷酸腺苷-肿瘤体外药敏检测结果指导临床化疗与患者的临床近期疗效有很好的相关性,对指导晚期卵巢上皮癌个体化化疗有的临床价值。 Objective To explore the clinical value of adenosine triphosphate - tumor chemosensitivity assay (ATP -TCA) in the guidance of the advanced epithelial ovarian carcinoma patients treated with chemotherapy. Methods Twenty cases of the advanced epithelial ovarian carcinoma at the Department of Gynecology in the Affiliated Hospital of Zunyi Medical College were analyzed retrospectively. This study was divided into the control group including 11 cases treated with the first -line chemotherapy (plati- num and paclitaxel) and the experiment group including 9 cases treated with sensitive chemotherapeutic program. The short - term clinical effects of these 2 groups were compared. Results The short - term clinical effects in the experiment group were better than those in the control group ( Z = - 3. 636, P 〈 0. 001 ). Conclusion ATP- TCA -guided chemotherapy is significantly correlated with the short -term clinical effects and ATP - TCA might play an important role in the guidance of individualized chemother- apy for the advanced epithelial ovarian carcinoma.
出处 《遵义医学院学报》 2012年第6期507-509,共3页 Journal of Zunyi Medical University
关键词 卵巢上皮癌 三磷酸腺苷-肿瘤体外药敏检测 化疗 epithelial ovarian carcinoma adenosine riphosphate - tumor chemosensitivity assay chem-otherapy
  • 相关文献

参考文献5

二级参考文献17

  • 1田海梅,石晓燕,傅军,曹冬艳,张凯,吴令英,王金万,张伟.ATP抗肿瘤药物敏感性检测技术与卵巢癌临床治疗的相关性研究[J].中华肿瘤杂志,2005,27(5):296-298. 被引量:17
  • 2张伟.生物荧光肿瘤体外药敏检测技术的临床应用[J].中华检验医学杂志,2005,28(12):1316-1319. 被引量:9
  • 3Kris MG, Benowitz SI, Adams S, et al. Clinical cancer advances 2010: Annual report on progress against cancer from the american society of clinical oncology [ J]. J Clin Onco, 2010, 28 (36):5327.
  • 4Liu J, Matulonis UA. New advances in ovarian cancer [ J].Ontology, 2010, 24 (8):721.
  • 5Neubauer H, Stefanova M, Solomayer E, et al. Predicting resistance to platinum-containing chemotherapy with the ATP tumor ehemosensitivity assay in primary ovarian cancer [ J ]. Anticancer Res, 2008, 28 (2A):949.
  • 6Han SS, Choi SH, Lee YK, et al. Predictive value of individualized tumor response testing by ATP-based chemotherapy response assay in ovarian cancer [ J ]. Cancer Invest, 2008, 26 (4) : 426.
  • 7Cree IA. Chemosensitivity and chemoresistance testing in ovarian cancer [ J]. Curr Opin Obstet Gynecol, 2009, 21 (1):39.
  • 8CA-125 definitions agreed by GCIG November 2005. http : // ctep. cancer, gov/resources/gcig/respdef- nov2005, doc.
  • 9Rustin GJ, Quinn M, Thigpen T, et al. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer) [J]. J Natl Cancer Inst, 2004, 96 (6):4-87.
  • 10Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada [ J ]. J Natl Cancer Inst, 2000, 92 (3) : 205.

共引文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部